Published Study Demonstrates the Association Between Immunovaccine’s Proprietary Immune-targeted Delivery Technology

- January 31st, 2018

Immunovaccine (TSX:IMV) a clinical stage immuno-oncology company, announced the publication of a preclinical study using magnetic resource imaging (MRI) to follow cancer peptide uptake in tumor models, and to correlate this immune activation to the resulting anti-cancer T cell activity. As quoted in the press release: The Journal of Biomedical Science study, titled “Unique Depot Formed by …

Immunovaccine (TSX:IMV) a clinical stage immuno-oncology company, announced the publication of a preclinical study using magnetic resource imaging (MRI) to follow cancer peptide uptake in tumor models, and to correlate this immune activation to the resulting anti-cancer T cell activity.
As quoted in the press release:

The Journal of Biomedical Science study, titled “Unique Depot Formed by an Oil Based Vaccine Facilitates Active Antigen Uptake and Provides Effective Tumour Control,” compared the mechanism of action (MOA) of Immunovaccine’s platform for immunotherapeutic stimulation with other technologies. In the study, published on January 27, 2018, researchers tracked how the cancer peptides were trafficked from the injection site to immunogenic activation in the lymph nodes.

Click here to read the full press release.

  Life Science and Healthcare Investing report cover

Life Science and Healthcare Investing in 2021

 
The life science and healthcare market is a booming, multi-billion dollar industry. Read our 2021 life science outlook report!
 

Get the latest Biotech Investing stock information

Get the latest information about companies associated with Biotech Investing Delivered directly to your inbox.

Biotech Investing

Select None
Select All

Leave a Reply